Want to stay informed with market insights and investing ideas from Morningstar? Sign up for our weekly Investor Focus newsletter here.
In this week’s newsletter:
- What’s the Q3 Outlook for the FTSE 100?
- EasyJet Shares Jump as Apollo Bid Raises Odds of Bidding War
- GSK Share Price: Is This FTSE 100 Pharma Stock Making a Comeback?
- How Will the UK Pay for Its £300 Billion Defense Spending Plan?
- Jeremy Grantham on SpaceX: It Will Be Amazing If It Doesn’t Collapse
- Asia Funds Dominate in 2026 Amid AI Infrastructure Boom
- The Best-Performing ETFs for UK Investors
It’s not every day that investors see a bidding war for a loss-making low-cost airline. But that’s what has happened with easyJet EZJ and it’s sent the stock soaring, having recovered from a nose-dive earlier this year. Analysts are now saying this could turn into an outright bidding war between two US money managers. Read more here.
EasyJet shareholders may be celebrating the news, but concerns remain that this latest privatization bid is part of a trend for a shrinking menu of domestic investments for UK stock investors. If you haven’t yet watched my interview with Gold-rated Fidelity Special Situations fund manager Alex Wright on this very topic, you can catch up here.
Elsewhere in the UK, the nominations process for a new Labour Party leader now looks certain to result in a political coronation for Andy Burnham. Markets, investors, and savers, all want to know who Burnham’s chancellor will be. Defense, pensions, and personal taxation are all at stake. Check out our site next week for the full explainer. For more on how this could affect UK markets in the third quarter, check out our Q3 UK market outlook here. For a look back at Q2, check out our analysis of the best- and worst-performing ETFs here.
It’s now been nearly a month since SpaceX SPCX went public and, not surprisingly, it’s been a volatile ride so far for investors. This week the company dropped to USD 149 per share – below its USD 150 IPO price – having traded has high as $225.64. Outspoken investor strategist and GMO co-founder Jeremy Grantham tells Morningstar that the SpaceX IPO was “the craziest IPO in the history of man,” and that it will be amazing if the rocket and AI company doesn’t collapse.
Ollie Smith, Senior Editor, Morningstar UK
